Losartan Potassium Tablets Recalled for Elevated AZIDO Impurity Levels
Strides Pharma Inc. is recalling Losartan Potassium 50 mg tablets distributed nationwide due to AZIDO impurity levels exceeding acceptable FDA manufacturing standards.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II drug recall with no reported illnesses, injuries, or hospitalizations. The hazard—manufacturing contamination with elevated AZIDO impurity levels—represents a potential risk of harm, but no adverse effects have been documented. Per the rubric, risk-of-harm products without reported injury receive a High (3) severity rating.
Plain-English summary
Strides Pharma Inc. is recalling specific batches of Losartan Potassium Tablets, USP, 50 mg (Rx Only), due to Current Good Manufacturing Practice (CGMP) deviations. Testing identified AZIDO impurity levels in affected batches that exceeded acceptable limits established by FDA standards.
The recalled product was manufactured by Vivimed Life Sciences Private Limited (India) and distributed nationwide by Strides Pharma Inc. Affected batches include multiple lot numbers with expiration dates ranging from June 2022 through January 2023. Approximately 381,456 bottles are involved in this recall.
Patients currently taking affected batches should not stop taking their medication without consulting a healthcare provider, as abrupt discontinuation of blood pressure medication can be harmful. Patients should contact their pharmacy or healthcare provider to determine if they have received affected product and to discuss appropriate next steps. Healthcare providers and pharmacies should quarantine affected product and return it to their wholesaler or contact Strides Pharma Inc. directly.
The recalled product
- Product
- LOSARTAN POTASSIUM (LOSARTAN POTASSIUM)
- Brand
- LOSARTAN POTASSIUM
- Manufacturer
- Strides Pharma Inc.
- Category
- Drug — Antihypertensive
- Hazard
- chemical-contamination
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- NDC 64380-934-05 Lot 7901146A
- 7901147A
- 7901148A & 7901149A
- Exp Date Sep-22
- Lot 7901279A
- 7901280A
- 7901281A
- 7901282A
- 7901283A & 7901284A
- Exp Date Nov-22
- Lot 7901359A
- 7901360A & 7901361A
- Exp Date Dec-22
- Lot 7901362A
- 7901406A
- 7901407A
- 7901408A & 7901409A
- Exp Date Jan-23. 64380-934-08 Lot 7901008A & 7901009A
- Exp Date Jun-22
- Lot 7901150A & 7901151A
UPCs (9)
- 0364380933052
- 0364380935056
- 0364380935087
- 0364380935049
- 0364380934042
- 0364380933045
- 0364380934080
- 0364380933083
- 0364380934059
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · LOSARTAN POTASSIUM
- HighLosartan Potassium Tablets Recalled for Blue Plastic Contamination
FDA (Drugs) · 2023-07-12
- HighLosartan Potassium tablets recalled for elevated AZIDO impurity
FDA (Drugs) · 2022-07-06
- HighLosartan Potassium Tablets Recalled for Elevated AZIDO Impurity Levels
FDA (Drugs) · 2022-07-06
- HighLosartan Potassium Tablets Recalled for Manufacturing Impurity Issues
FDA (Drugs) · 2022-07-06
- ModerateLosartan Potassium tablets recalled for excessive AZIDO impurity
FDA (Drugs) · 2022-06-08
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- ModerateGas-X Simethicone 125 mg softgels recall for incomplete labeling
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27